#TumorBoardTuesday
We have not heard any updates from #SABCS24 yet!

📢So join us Tuesday, 01-14-25 at 8PM ET here & on the BlueSky network as @dr-rshatsky.bsky.social & @zoezhang.bsky.social🗣️SERDS & novel Tx for HR+ #breastcancer

RT and bring others into the discussion‼️ #TumorBoardTuesday

🧠And while we finalize the case details, collect FREE #CME
👉🏽

➡️Before @dr-rshatsky.bsky.social & @zoezhang.bsky.social🗣️SERDS & novel Tx for HR+ #breastcancer , tell us your connection to this medical🩺discussion
👇👇🏼👇🏾integrityce.com/TBT2024

🔥#TumorBoardTuesday is a must-attend!
🧑‍🔬Join @marklewismd @CatherineaOC 07.25.23 8pm ET as they explore differentiating midgut & PNETs
🔥Be part of an insightful discussion!
🧠Get FREE #CME credits as we finalize the case
👉🏽Visit for more info #OncTwitter https://t.co/ZFiIauawhpintegrityce.com/TBT2023
@marklewismd @CatherineaOC @MPishvaian @JohnEbbenMDPhD @ferguskeane2 @CentralParkWMD @EileenMOReilly @PanCAN @letswinpc @PamelaKunzMD @ShaalanBeg @AaronGoodman33 You don't want to miss this #PanCan #TumorBoardTuesday!! 👆🏼 Set an alarm NOW & tell the neighbors🔥
@shafiarahman_ @oncologician @OncoThor @drjasonstarr @NirajGusani @BenWestphalen @realbowtiedoc @RachelRiechelm2 @HalletJulie @helops79 @AGangiMD @shimaghavimimd @peterhoseinmd… twitter.com/i/web/status/1…

🫘Don't miss #TumorBoardTuesday!

🫘Join @brian_rini @katy_beckermann on 07.18.23, 8pm ET for IO refractory #RCC!

💬Engage here for an insightful discussion!

🧠As we finalize the case, grab FREE #CME credits.

👉🏽Visit for more info. #OncTwitter https://t.co/gwxFdkpcgtintegrityce.com/TBT2023
@brian_rini @katy_beckermann @AlbigesL @ChungHanLee3 @MPishvaian @JohnEbbenMDPhD @motzermd @DrChoueiri @DrDanielHeng @ReneeSaliby @montypal @HHammersMD Set an alarm to join #TumorBoardTuesday this week!
@DrRanaMcKay @AmandaNizamMD @tompowles1 @QingZhangLab @YuWeiChenMD @JessicaHawleyMD @minaseconomides  @RahulBanerjeeMD @rafee_talukder @shilpaonc @MosheOrnsteinMD @AJangMD @LisaHenske @UroDocAsh @Uromigos @UROncDoc @JVentoMD… twitter.com/i/web/status/1…

🏝️Don't miss #TumorBoardTuesday!

🏝️Join @dradityabardia & @ArielleMedford on 07.11.23, 8pm ET for TROP2 TX in Localized TNBC!

💬Engage here for an insightful discussion!

🧠As we finalize the case, grab FREE #CME credits

👉🏽 for more info. #OncTwitter https://t.co/b1Ad7hGoHlintegrityce.com/TBT2023
@dradityabardia @ArielleMedford @MPishvaian @JohnEbbenMDPhD @JaniceTNBCmets @IanKropp @RebeccaDent @DrLisaCarey @YAbdouMD @BianchiniGP @NagiSaghir @Dr_Brian_Cox Be sure to set a reminder to join #TumorBoardTuesday this week! Spread the word!
@aftimosp @AiroBreast @MOliveira_MD @NicoleJacobi4 @AMJohnston1315 @TNBCFoundation @Ancora_AI @rleonferre @ElementoLab @ErikaHamilton9 @RenoHemonc @stolaney1 @sandycassanelli @antonyruggeri… twitter.com/i/web/status/1…

💥#ASCO23 had tx developments for #BreastCancer!

💥Tuesday 06.27.23 at 8pm ET @ilanaschlam @drsarahsam take us through 2L+ tx opts on a CDK4/6i

💬Join us here on #TumorBoardTuesday!

🧠While we finalize the case, collect FREE #CME
👉🏽👈🏼
#OncTwitter #BCSM https://t.co/poyOsFLZt7integrityce.com/tbt2023
@IlanaSchlam @drsarahsam @MPishvaian @JohnEbbenMDPhD @dradityabardia @ArielleMedford @LGerratana @StoverLab @AndreaMaliachi @elmayermd @hoperugo @kevinpunie Be sure to #TumorBoardTuesday this Tuesday!

@FAndreMD @KalinskyKevin @SusanGKomen @FilippoMontemu1 @mabelonc @drteplinsky @PTarantinoMD @MridulaGeorgeMD @mfrimawi @FernandoOnco @stolaney1 @maryam_lustberg @CharlesMilrod @OncBrothers @AWolff @jane_meisel @DrGattiMays… twitter.com/i/web/status/1…

🧬#TumorBoardTuesday is back this Tuesday after the brief #ASCO23 break!!

📆06.20.23 8pm ET
👨🏻‍🏫@SteveBialickDO @GinaDAmatoMD1👩🏻‍🏫
📰Selecting TKI in #GIST

🌈While we finalize the case, collect FREE #CME 👉🏽 👈🏼 #OncTwitter #Sarcoma https://t.co/cdVZreVknQintegrityce.com/TBT2023
@SteveBialickDO @GinaDAmatoMD1 @bvantine1 @JTrentMDPhD @WTapMD @MPishvaian @JohnEbbenMDPhD @CureSarcoma @and_oncology @dileo_palma @Robertasanfili @TonyOncDoc Please mark your calendar to join #TumorBoardTuesday's FIRST #Sarcoma case discussion this Tuesday!!
@GladdyLab @herbloong @NassifElise @ctosociety @CareSarcoma @Sarcoma_UK @Martamartin_r @SarcomaAlliance @DrSarcoma @DrAngelaLamarca @VKeedySarcomaMD @Sunil_G_Iyer… twitter.com/i/web/status/1…

🌻This Tuesday 05.16.23 at 8pm ET @drteplinsky @prarthnavb join #TumorBoardTuesday to take us through using baby Tam for high risk lesions & in #BreastCancer

💬Join us!

🧠While we finalize the case, collect FREE #CME

👉🏽integrityce.com/tbt 2023👈🏼#OncTwitter #BCSM @drteplinsky @prarthnavb @MPishvaian @JohnEbbenMDPhD @Dr_RShatsky @hmcarthur @DrSGraff @DrTimothyErick @MdVarvaras @sardesai_sagar @ZainabFatima100 @AnupamaN20 #TumorBoardTuesday

What to recommend for your patients who are high risk #BreastCancer?

👉🏽Join @drteplinsky @prarthnavb Tues 05/16/23 at 8PM ET

📊Respond to polls
Weigh in & bring citations🧾
Retweet & tag your colleagues
🏆Earn FREE CME: integrityce.com/TBT2023

1/6 #TumorBoardTuesday

🔬🧬@PGrivasMDPhD @rafee_talukder discussed variant histology #urothelialcarcinoma & cis-ineligible dz

➡️Thursday Case wrap up 🎀

🆓 #CME: answer 2 quick ❓
ALL CME 🔗: integrityce.com/TBT2023
CME eval🔗: integrityce.com/TBTeval23 2/6 #TumorBoardTuesday
Thurs Case🎀
Take🏠:
✅Variant hist UC changes tx
⬇️resp to plat 👉surg first, clin trial
✅Cis inelig mUC- acc approval: Enfortumab Vedotin + pembro 1L
✅Trials: 1L SG + IO, others

📚Here’s @PGrivasMDPhD @rafee_talukder’s thread
threadreaderapp.com/thread/1656086…

1/5 #TumorBoardTuesday

🧬No more waiting! Here’s our summary of @RachelRiechelm2 @jessrzanotti’s talk re: hypermut #NET. Can biomarker become clinically actionable?

🆓#CME: 2 quick❓
ALL CME 🔗: integrityce.com/TBT2023
CME eval🔗: integrityce.com/TBTeval231/5 #TumorBoardTuesday twitter.com/i/web/status/1… 2/5 #TumorBoardTuesday
Case🎀

Take🏠 messages:
✅ Hypermut(TMB>10) RARE in NET
✅ Post-tx w alkylator (CAPE/TEM)
✅Mixed results w IO monotx; studying dual IO, combos
✅ Repeat NGS if NET becomes more aggressive; ID new targets, hypermut

📚The thread: threadreaderapp.com/thread/1653549…

#TumorBoardTuesday

🔬🧬Tx of #EGFR Exon20 insertion has changed significantly. @LealTiciana @JennyCarlisleMD brought us up to speed at #TumorBoardtuesday

➡️Here’s the Thursday Case 🎀
🆓 #CME: 2 quick❓
ALL CME 🔗: integrityce.com/TBT2023
CME eval🔗: integrityce.com/TBTeval23 2/8 #TumorBoardTuesday
Thurs Case🎀
✅Next gen seq=ESSENTIAL. PCR misses EGFR exon20 ins!
✅CHRYSALIS: Amivantamab (EGFR/MET Bispecifc mAb) 2L
✅EXCLAIM: Mobocertinib (EGFR TKI) 2L
✅1L= Plat chemo; 2L= ami/mobo

📚 @LealTiciana @JennyCarlisleMD’s thread
threadreaderapp.com/thread/1651013…

No monkeying around!
👨🏻‍⚕️@tompowles1 @drfrankiejs👩🏼‍⚕️may be in UK, but they’re leading #TumorBoardTuesday on Tuesday!

📅03.28.23 at 8pm ET/12am BT
📰1L pembro or Nivo+Cabo?

🐵While case is finalized, collect FREE #CME (AMA & MOC)

🐒integrityce.com/tbt🙊#OncTwitter #RenalCancer @tompowles1 @drfrankiejs @MPishvaian @minaseconomides @JohnEbbenMDPhD @JineshGheeya @niklas_kluemper @EHeath4100 @Heer_Lab @MariaChiaraMCS @ReisLO @PGrivasMDPhD A tad bit of 🙊monkeying around in #TumorBoardTuesday land by attaching a sneak peak into @JohnEbbenMDPhD's wrap up image. 😉

The info is the same!
📅Tues 03/28/23
🕰️8pm ET/12am BT
☕️Cuppa with🇬🇧@tompowles1 👨🏻‍⚕️👩🏼‍⚕️@drfrankiejs
🗞️1L tx decision for #RenalCancer
#Urology @Uromigos

💥#EndometrialCancer TKI/IO safety data & AE mgmt webinar 💥┈┈┈ w @DrMMurphy & @drteplinsky ┈┈┈🔹#CME info 👉 bit.ly/3Vqtabi 👈 @BonumCE ┈┈┈🔸Supported by edu grants from Eisai & @Merck 🔹#TumorBoardTuesday #gyncsm #OncTwitter twitter.com/i/broadcasts/1… 1/#TumorBoardTuesday #OncTwitter

#1:Answer #PreTest❓🔗bit.ly/EC_AEs_TBTpre
#2:Tell us who u are👇
#3:🔁Retweet & tag colleagues

🧧#CME ℹ️bit.ly/3Vqtabi
Supported by edu grants from Eisai & @Merck

🟢Where r u in your career?

1/#TumorBoardTuesday #OncTwitter

🗓️TODAY🗓 w @DrMMurphy & @DrTeplinsky
🎥#EndometrialCancer - Mnging TKI/IO AEs

#CMEℹ️ bit.ly/3Vqtabi
Support by edu grants from Eisai & @Merck

🚨Be ready @ 8p ET/5p PT
✅Answer #PreTest👇
🔁RT & tag 🩺

🟢Where r u in your career? 2/#TumorBoardTuesday #OncTwitter #GynCSM #gynonc
#CME🔗bit.ly/3YRDkog

🟢#PreTest Q 1️⃣
📊Diarrhea, nausea, & vomiting are common GI toxicities associated w pembro + lenvatinib combo therapy

🟢Which other tox may occur if these GI toxicities are not effectively managed?

1/#OncTwitter #TumorBoardTuesday #MedTweetorial 🧵

✅#EndometrialCancer AE deep dive🤿
🧪Trial results
🔬Tox for TKI-ICI
w @DrMMurphy @MeganLeigh127 & us!

🆓#CME @BonumCe🔗bit.ly/3VBGJEJ
Supported by edu grants from Eisai & @Merck

🟢What's your specialty? 2/#TumorBoardTuesday #BonumCE #OncTwitter #gyncsm #gynonc #EndometrialCancer #MedTweetorial

🆓 CME > full info➕ref list🗒️& program archive
👉bit.ly/3VBGJEJ

🔑#CME info👇

@MPishvaian #GI23
Coming at you from #TumorBoardTuesday
The TOP 🎯💊abstracts for ASCO-GI 2023

➡️Starting with MSI-H cancers:
✅Path CR neoadj ICI MSI-H GI Cancers
👁️L Pappas, Abs 43, Pos B18

✅A Ph 2 trial of toripalimab in adv tumors with POLE/POLD1🧬mut
👁️Y Jin, Abs 802, Pos M17 @MPishvaian #GI23
➡️Exciting updates in HER2➕Cancers

✅A Ph 2 trial of trast➕pertuz vs. iri➕cetuximab for HER2➕mCRC: SWOG S1613
👁️KPS Raghav, Abs 140, Pos G18

✅Zanidatamab➕chemo as 1⃣st-line Tx for HER2➕met GE jxn AdenoCa
👁️Ea Elimova, Abs 347, Pos E8

1/🛎️#TumorBoardTuesday #OncTwitter #NephTwitter
#RenalCell wk continues🔁

🗓️Thu 12.15 @ 8p ET

⚙️Mnging AEs w TKI/IO combos

#CME ℹ️🔗bit.ly/3iLN6aX
Supported by edu grants from Eisai & @Merck
🚨Be ready 4 tmrw!
✅Answer #PreTest polls👇
🔁Retweet & tag colleagues🩺 2/ 🏆Claim 🆓#CME 🔛 bit.ly/3iLN6aX

Answer Pre Polls Qs 👇today
🟢Where r u in your career?

1/ #OncTwitter #NephTwitter #TumorBoardTuesday
✅#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann

🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt

🆓#CME @BonumCe🔗bit.ly/3VDaK81
Support by edu grants from Eisai & @Merck

🟢What's your specialty? 2/ #TumorBoardTuesday #BonumCE #RenalCell #OncTwitter #NephTwitter
🆓#CME info ➕ full ref list🗒️ 👉 bit.ly/3VDaK81

✳️The critical elements👇

#TumorBoardTuesday #ASCO2022

📢@ASCO is only a few days away & we really wanted to put out our top abstracts to👀for

🙏note - we viewed several thousand titles - so we definitely may have missed some‼️
👉And these are not in any particular order

✅But enjoy, RT, and reply😀 #TumorBoardTuesday #ASCO2022
"Emerging"🎯💊
✅Dr. Jones👨‍🏫the Ph2 FAKTION trial of fulv/capi vs fulv/placebo for Breast Ca
➡️Capi⬆️mOS by 6 mos
➡️This⬆️jumped to 19 ms if the tumor harbored PIK3CA or AKT1 activating OR PTEN inactivating🧬mutations
🔎Breast Ca Oral Abstract # 1005

🙏🏽Thank you @Latinamd @GDutcherMD for an informational & exhilarating #TumorBoardTuesday!!

🏆Remember 🆓CME

Look for the Case Wrap Up🎀 05/26/22

📅Mark your calendar for 𝙉𝙀𝙓𝙏 𝙒𝙀𝙀𝙆 05/31/22 when our own @MPishvaian joins us for a breakdown of #ASCO22 abstracts!! 🏝#TumorBoardTuesday education is beyond Twitter - we offer🆓CME!!

🫁Before you run off exploring, pick up your🏆#CME by answering quick questions regarding a case similar to @Latinamd’s‼️

🔗ALL CME: integrityce.com/tbt

🔗CME eval: integrityce.com/TBTEval

👇🏽🎁

#TumorBoardTuesday

🎓We have had some highly educational🗣️on tumor biomarkers
👍This week’s conversation will NOT disappoint

📢Join us as @Latinamd & @GDutcherMD from @SylvesterCancer discuss MET Exon 14 skip mutations in #NSCLC #Miami #TumorBoardTuesday

@Latinamd & @GDutcherMD @TumorBoardTues 🗣️
📅Tuesday, 05/24/22 at🕗8PM ET
📊✅the polls
⚖️in & bring citations🧾
🔁Retweet & tag your🩺colleagues
🏆Earn your🆓CME and MOC integrityce.com/tbt

And B4⃣the case:
🧐tell us where you are in your🩺journey
👇

1/12 #TumorBoardTuesday
2L treatment in #HER2+ breast cancer #MBC is 🤯! @PTarantinoMD led us through latest evidence👩‍⚖️

➡️Here's the Thurs Case🎀
👉Grab🆓 #CME credit by answering quick❓
ALL CME 🔗: integrityce.com/tbt
CME rationale🔗: bit.ly/3NnreMW
Here we go! 2/12 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:
⬆️ options to tx HER2+ #MBC
✅T-DXd >T-DM1 in 2L setting (DESTINY BREAST-03)
✅Beware ADC tox- think 🫁pneumonitis & GI w T-Dxd
✅ADC design is 🗝:
➡️Need to consider DAR, linker, ability to cause ADCC
✅ADC + IO= open ❓